4.6 Article

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 148, Issue 6, Pages 879-889

Publisher

WILEY
DOI: 10.1111/j.1365-2141.2009.08033.x

Keywords

CD123; single-chain Fv; leukaemic stem cell; immunotoxin; bispecific antibody fragments

Categories

Funding

  1. DFG (Deutsche Forschungsgemeinschaft
  2. German Research Foundation)
  3. Bayerische Eliteforderung (Bavarian Scholarship Foundation)
  4. German Jose-Carreras Leukaemia-Foundation
  5. Wilhelm Sander Foundation, Neustadt, Germany [2007.049.1]
  6. Stiftung Deutsche Krebshilfe
  7. Beitlich Foundation, Tubingen
  8. Association 'Kaminkehrer helfen krebskranken Kindern'

Ask authors/readers for more resources

P>Four new single-chain Fv antibody fragments (scFvs) specific for the human leucocyte surface antigen CD123 (interleukin-3 receptor alpha) were generated to achieve preferential targeting of leukaemia stem cells (LSCs) in acute myeloid leukaemia (AML). The scFvs were isolated from a phage display library generated with spleen RNA from mice, immunized with a fusion protein consisting of the extracellular domain of CD123 and the Fc domain of a human immunoglobulin G1. The scFvs displayed CD123-specific binding on tumour cells (binding constants (K-D) 4 center dot 5-101 nmol/l). The scFv with the highest affinity was used to design two cell death-inducing molecules. First, an immunotoxin, a fusion protein with truncated Pseudomonas Exotoxin A, induced potent apoptosis of AML-derived MOLM-13 and SKNO-1 cells at nanomolar concentrations. Second, the fusion to another scFv, specific for the low affinity Fc gamma-receptor III (CD16), created a bispecific single chain Fv (bsscFv). This bsscFv [123 x ds16] mediated potent lysis of AML-derived MOLM-13, THP-1 and SKNO-1 cells in antibody-dependent cellular cytotoxicity (ADCC) reactions at picomolar concentrations. The recruitment of CD16-positive effector cells for the lysis of AML cells via CD123 represents a novel combination with attractive prospects for future clinical testing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available